Clinical Trials Sponsored by Leo W. Jenkins Cancer Center

Total 860 results

H. Lee Moffitt Cancer Center and Research Institute
Blueprint Medicines Corporation

Recruiting

Avapritinib With Decitabine in Patients With SM-AHN

Systemic Mastocytosis With an Associated Hematologic Neoplasm

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Recruiting

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

Myelodysplastic Syndromes | Anemia | Myeloproliferative Neoplasm

United States
Modulation Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

Uveal Melanoma | Metastatic

United States
H. Lee Moffitt Cancer Center and Research Institute
Anixa Biosciences, Inc.

Recruiting

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

Ovarian Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Progenics Pharmaceuticals, Inc.

Recruiting

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

Recurrent Prostate Cancer | Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
OncoSec Medical Incorporated

Active, not recruiting

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Secura Bio, Inc.

Active, not recruiting

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Hodgkin Lymphoma | Non Hodgkin Lymphoma | Myeloma | Lymphocytic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer | Extensive-stage Small Cell Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Active, not recruiting

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Metastatic Melanoma | Metastasis to Brain

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

GVHD | Graft-versus-host-disease | GVHD, Acute

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis; Celgene Corporation

Active, not recruiting

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Varian Medical Systems

Withdrawn

Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer

Pancreatic Cancer | Resectable Pancreatic Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)

Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Nestle Health Science

Withdrawn

Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢA

United States
H. Lee Moffitt Cancer Center and Research Institute
Roche Pharma AG

Terminated

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Adenocarcinoma | Colon Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
BTG International Inc.

Completed

Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma

Cholangiocarcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
BTG International Inc.

Completed

Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

Pancreatic Cancer | Liver Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis; Genentech, Inc.

Completed

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

Head and Neck Cancer | Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Terminated

Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

Myelodysplastic Syndromes

United States
ProCertus BioPharm, Inc
H. Lee Moffitt Cancer Center and Research Institute

Withdrawn

Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy

Radiodermatitis

United States
Centre Francois Baclesse
National Cancer Institute, France; Ligue contre le cancer, France

Completed

Management of Cognitive Difficulties After Cancer Treatments in Women Treated for Breast Cancer: Feasibility Study (Step 1 of the Cog-Stim Protocol) (COG STIM)

Breast Cancer

France
University of Oklahoma
M.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Florida and other collaborators

Recruiting

Mobile Contingency Management for Smoking Cessation (P3)

Smoking Cessation

United States
Opsona Therapeutics Ltd.
M.D. Anderson Cancer Center; Montefiore Medical Center; New York Presbyterian... and other collaborators

Completed

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Opsona Therapeutics Ltd.
M.D. Anderson Cancer Center; Montefiore Medical Center; New York Presbyterian... and other collaborators

Completed

Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
H. Lee Moffitt Cancer Center and Research Institute
National Comprehensive Cancer Network; Puma Biotechnology, Inc.

Recruiting

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Gastric Cancer | GastroEsophageal Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); BioGene Life Science

Completed

Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects

Pancreatic Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Astex Pharmaceuticals, Inc.

Completed

Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide

Unspecified Adult Solid Tumor, Protocol Specific

United States
H. Lee Moffitt Cancer Center and Research Institute
The V Foundation for Cancer Research; Kay Yow Cancer Fund

Completed

Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer

Peritoneal Diseases | Ovarian Diseases | Fallopian Tube Diseases | Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Centre Leon Berard
Novartis; National Cancer Institute, France

Recruiting

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas (AMPHISARC)

Advanced Soft-tissue Sarcoma | Metastatic Soft-tissue Sarcoma

France
University of Nebraska
National Cancer Institute (NCI); H. Lee Moffitt Cancer Center and Research...

Completed

Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer

Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Terminated

A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma

Multiple Myeloma

United States
Luo Cong

Completed

The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic Cancer

China
Luo Cong

Completed

Machine Learning for Recurrence Risk of Pancreatic Cancer After Radical Resection (PaC)

Pancreatic Cancer

China
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); BioGene Life Science

Completed

Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects

Pancreatic Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Pfizer; Oncovir, Inc.

Completed

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Sanofi; Genentech, Inc.

Completed

Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma

Ovarian Cancer | Fallopian Tube Cancer | Malignant Tumor of Peritoneum

United States
Douglas Tyler
M.D. Anderson Cancer Center; Merck Sharp & Dohme LLC; Duke University; H. Lee Moffitt...

Completed

Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion

Melanoma

United States
Institut de Recherche Clinique sur les Cancers...

Unknown

Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Leukemia

France
Centre Georges Francois Leclerc
Ligue contre le cancer, France

Completed

Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults (SIB-IMRT)

Glioblastoma

France
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company

Recruiting

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Acute Lymphoblastic Leukemia | B-Cell Lymphoblastic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Recruiting

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Ocular Melanoma | Uveal Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Regeneron Pharmaceuticals; Sanofi-Synthelabo

Recruiting

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Merkel Cell Carcinoma | Neuroendocrine Carcinoma of the Skin | Trabecular Carcinoma of the Skin

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals; RECORDATI GROUP

Completed

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Neuroendocrine Tumors | Carcinoid Tumors

United States
H. Lee Moffitt Cancer Center and Research Institute
University of South Florida

Completed

Physical Activity for Advanced Stage Cancer Patients

Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Completed

Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
University of South Florida

Completed

Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer

Ovarian Cancer

United States

Clinical Trials Sponsored by Leo W. Jenkins Cancer Center

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations